Manuel Serrano

Director, Institute for Research in Biomedicine

Manuel Serrano obtained his PhD in 1991, from the Universidad Autónoma de Madrid. From 1991 to 1996, Serrano worked in the team of David Beach in Cold Spring Harbor Laboratory, NY. During this period, Serrano made his most important discovery with the identification and characterization of the gene p16, one of the most important genes for anti-cancer protection. Serrano returned to Spain in 1997 to lead a research group, first at the National Center of Biotechnology (CNB), and then, from 2003 to 2017, at the Spanish National Cancer Research Center (CNIO), both in Madrid. In 2017, Serrano moved to the Institute for Research in Biomedicine (IRB), in Barcelona.

Manuel Serrano is internationally recognized in the field of tumor suppression. In addition to the discovery of p16, one of his main discoveries has been the identification of cellular senescence as a main anti-oncogenic response. Recently, his laboratory has also shown that cellular senescence participates in several tissue remodeling processes during embryo development. The Serrano team was pioneer in the generation of genetically-modifed mice resistant to cancer and found a link between tumor suppressor genes and aging.

Founder of Iduna Therapeutics and Academy for Health & Lifespan Research.

Details last updated 04-Mar-2020

Mentioned in this Resource

Academy for Health and Lifespan Research (AHLR)

World's aging researchers unite to accelerate breakthroughs in longevity

Manuel Serrano is also referenced in the following:

Altos Labs

Biotechnology company focused on cellular rejuvenation programming

ARDD 2021 - 8th Aging Research and Drug Discovery Meeting

31-Aug-2021 to 03-Sep-2021

Online event about latest progress in the molecular, cellular and organismal basis of aging organized by University of Copenhagen chaired by Morten Scheibye-Knudsen, Daniela Bakula and Alex Zhavoronkov, and with many speakers.